Semaglutide significantly reduces all-cause mortality in non-diabetic obese patients, particularly by lowering infection-related deaths during the COVID-19 pandemic. However, the study’s findings should be interpreted with caution due to potential competing risks and unique pandemic circumstances.
Fresh scrutiny of post-Covid spending reignites yearslong tension over emergency stockpiles
WASHINGTON — For four years, Democrats and Republicans have routinely clashed over funding to curb the Covid-19 pandemic and prepare for future crises. Now, the
May 23, 2024